Search This Blog

Monday, June 2, 2014

Phase 3 Study Evaluating Yervoy® (Ipilimumab) for Melanoma in an Adjuvant Setting Meets Primary Endpoint of Recurrence-Free Survival | BMS Newsroom

Phase 3 Study Evaluating Yervoy® (Ipilimumab) for Melanoma in an Adjuvant Setting Meets Primary Endpoint of Recurrence-Free Survival | BMS Newsroom

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.